Forward Pharma AS Gets a Buy from Jefferies

By Jason Carr

Jefferies analyst Brian Abrahams reiterated a Buy rating on Forward Pharma AS (NASDAQ: FWP) today and set a price target of $41. The company’s shares opened today at $21.51.

According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 10.9% and a 54.8% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Proteostasis Therapeutics Inc, and Achillion Pharmaceuticals.

Forward Pharma AS has an analyst consensus of Moderate Buy, with a price target consensus of $41.

Based on Forward Pharma AS’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $0 and GAAP net loss of $11.07 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $16.84 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Forward Pharma is a biopharmaceutical company which engages in the research and production of medicinal treatment for multiple sclerosis and psoriasis. It focuses on the immunomodulatory compound dimethyl fumarate (DMF) and its derivatives. The company was founded by Florian Schönharting on July 1, 2005 and is headquartered in Copenhagen, Denmark.